I'll be delivering you four brand new IPO dossiers within the next week. Today, as promised, I want to explain to you what's been happening with many of the newly launched IPOs and why we've been avoiding them.
This year's impressive achievements for the cannabis industry will pale in comparison to what is coming. Part of what's fueling our optimistic view is not what's on the books, but what's on deck at the state and federal level.
There are still riches to be made from medical cannabis. Maryland showed it this month by smashing annual estimates for sales. And a New York company just made almost $50 million by selling its license before ever selling any actual marijuana.
It's difficult to see a stock you recently bought go down. But as those who sold during Canopy Growth's three significant declines dating back to 2015 would attest, now is not the time to lose our resolve.
The last week shaped up to be a historic one for the cannabis industry. But as impressive as last week was, this week is shaping up to be even bigger. That's because you can bank on one recurring situation that inspires the titans of industries to try and outdo each other.
It's time to add two more cannabis names to the NYSE scoreboard. This week, two of the big five Canadian producers join their fellow colleagues in migrating to a massive U.S. exchange - a trend our Executive Director isn't expecting to stop anytime soon. But that doesn't mean investors should rush out and snap up shares. Instead, he's got his eyes on a few other up-and-comers that offer even greater potential.